Concorde International Group (NASDAQ: CIGL) is a diversified provider of medical aesthetic and personal care services, as well as consulting and practice management solutions for healthcare providers. The company operates a network of medical spa facilities offering a range of non‐invasive and minimally invasive procedures such as injectables, laser treatments, skin rejuvenation, and body contouring. In addition to its clinical services, Concorde offers comprehensive back‐office support, including billing, credentialing, vendor relations, and compliance management, allowing practitioners to focus on patient care while optimizing operational efficiency.
Since its founding in 2015, Concorde has expanded through a combination of organic growth and strategic partnerships, establishing a presence across multiple states in the U.S. and select international markets. The company’s integrated platform enables physician partners to leverage Concorde’s purchasing power for medical supplies, negotiate favorable terms with device manufacturers, and access leading‐edge technology without the capital outlay traditionally required. This model has attracted dermatologists, plastic surgeons, and other healthcare professionals seeking to grow their aesthetic practices under a proven management framework.
Concorde’s product portfolio extends beyond in‐office treatments to include proprietary skincare lines, patient education resources, and training programs for medical professionals and support staff. The company hosts regular workshops and certification courses on the latest aesthetic techniques, ensuring that its network remains at the forefront of innovation and safety standards. By combining clinical excellence with standardized operational practices, Concorde aims to deliver consistent patient experiences while maintaining rigorous quality controls.
Leadership at Concorde International Group is anchored by CEO Gary Polikos, who brings over two decades of healthcare management experience, and COO Elaine Tang, a specialist in medical device commercialization and practice operations. Under their guidance, the company continues to refine its integrated service offerings, pursue new market opportunities, and strengthen its partnerships within the rapidly evolving aesthetic medicine sector. With a focus on scalable growth and enhanced patient outcomes, Concorde is positioned to support the expanding global demand for non‐surgical cosmetic and wellness solutions.
AI Generated. May Contain Errors.
Free CIGL Stock Alerts